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Objective:
Pathologic nodal staging employing the technique of lymphatic mapping and sentinel
lymph node (SLN) biopsy has become the standard of care for patients with invasive
breast cancer.1 Most surgeons utilize a radioactive tracer, with or without preoperative
lymphoscintigraphy, alone or in conjunction with a vital blue dye to identify the
pertinent nodes.  The literature suggests that all nodes which have gamma counts >
10 times the background count should be considered sentinel nodes and retrieved2,
as should all clinically suspicious nodes and any with blue dye. There is literature
describing the number of SLNs that should be removed to minimize the false negative
rate,3,4,5,6 but these all represent the results of multiple surgeons and do not consider
the possible impact of increased experience. At our institution we utilized a single
surgeon, longitudinal database to determine the degree to which the SLN counts
correlate to the presence of metastasis and if we could identify an optimal number of
SLNs to remove to minimize false negative rate and the number of nodes retrieved.

Methods:

Conclusions:
Table 1. Patient Characteristics

Age

29-87
Mean 55

Gender

Female: 150
Male: 2

Tumor Type

Invasive Ductal: 136
Invasive Lobular: 16

Tumor Size

0.3-6.5 cm
Median 1.7 cm

ER Status

Positive: 126
Negative: 22
Not Reported: 4

Her 2 Status

Positive: 25
Negative: 122
Not Reported: 5

Number of Sentinel Nodes

1-6
Median: 3

Parients with Disease Past The Sentinel Nodes

29 of 116 patients (25%)

Figure 1. Patient Inclusion Criteria

Figure 2. Graph showing the
percentages of metastases found in the
hottest nodes.  
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• O
 f the original 823 patients in which SLN biopsy was attempted, 790 procedures had
successful identification of at least 1 SLN (96%).  
• There were 25 procedures in which a SLN was unable to be identified (3%) and 8
false negative procedures (1%)
• The node with the highest count was positive for metastatic disease in 105 (69%).  
• Removing the two nodes with the highest counts identified 140 (92%) node positive
patients.

Table 2. Metastases in the hottest nodes. Over the last two years of
the study the metastasis was more frequently found in the hottest node.

Metastases in the Most
Radioactive Node

Metastases in Two
Most Radioactive Nodes

1997-2008

79/120 (65%)

110/120 (91%)

2009-2011

26/32 (81%)

30/32 (93%)

Chi Square

p = 0.000104

p = Not Significant

Time Frame

References:

100
90
80
70

Percent

• R
 etrospective review of a prospectively maintained database.
• Chronicles a single surgeon’s breast cancer SLN
biopsy experience from 1997-2011.
• The first seven years routinely using the dual tracer
technique and the final seven utilizing radioisotope
routinely and blue dye for inability to perform
cutaneous mapping.  
• 823 SLN procedures were attempted
• 152 patients (19%) met the inclusion criteria of at least
one positive SLN and one negative SLN and mapping
performed by radioactive counts (see Figure 1).  
• Patients that had a failed mapping or had only blue
dye used in their mapping were excluded.  
• We then correlated the SLN radioactive counts and the pathology for each patient.  
The presence of metastasis in the most radioactive node(s) was then noted.  
• Chi Square analysis was used to compare the rates of identification of metastasis in
the most radioactive nodes.  

Results:

Photograph 1. Sentinel lymph node both
blue and hot with lymphatic channel
from 2004.

We employed a prospectively collected database of 823 consecutive lymphatic
mapping/sentinel node biopsies for breast cancer performed by a single surgeon,
to discern whether a surgeon can limit the number of radioactive nodes he or
she removes.  This is increasingly important given the trend towards eliminating
intraoperative nodal assessment for metastases.  In that subset of our node positive
patients who had at least one negative SLN, removing only the most radioactive node
would have under staged almost one-third (31%) of patients while removing the two
most radioactive nodes under stages only 8%.  These data, from a single surgeon, are
concordant with previously published findings from larger databases documenting
the experiences of multiple surgeons.4,7,8 For reasons that are unclear, there is a
statistically significant improvement of sensitivity in finding metastases in the most
radioactive SLN seen with increasing experience; the biologic rationale for this is
unclear and the false negative rate (6%) would still prove unacceptable.  For maximum
accuracy, we will continue to remove all nodes with radioactive counts greater than
10% of the hottest node and we will utilize blue dye for those procedures in which
radioisotope mapping fails.   

60

Hottest Node

50

Hottest 2 Nodes

40

Hottest 3 Nodes

30
20
10
0
1997-2011

1997-2008

2009-2011

Years

• R
 emoving the two nodes with the highest counts resulted in a false negative rate of
2.6%.
• In the final 2 years (2009-2011) of data collection, 26 of 32 of the study cohort had
the metastasis identified in the node with the highest radioactive counts (81%)
• In only 2 of the 32 cases done during 2009-2011 were the metastasis not found in
one of the two most radioactive nodes.
• In only 1 of the 152 cases done were the metastasis not found in one of the three
most radioactive nodes.
• When comparing the rates of identifying the metastasis in the single most
radioactive node between 1997-2008 and 2009-11, the difference was statistically
significant (p=0.000104), but there was no difference when comparing rates for the
two most radioactive nodes.
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